Enhancing the study of cancer with PowerAI Vision
Could AI tools built on IBM’s POWER systems make a difference to standards of care for cancer patients?
Oxford Cancer Biomarkers (OCB) collaborated with IBM and Meridian IT to identify patients who would benefit from chemotherapy following surgery.
Chemotherapy involves exposure to life-threatening toxicity. OCB investigate tissue samples from colorectal cancer patients, searching out biomarkers that indicate whether chemotherapy is an effective course of action after the removal of tumours.
With PowerAI Vision, OCB developed an object detection model for identifying biomarkers that allowed them to analyze images ten times faster - and test more patients at the same time.
Come and see how IBM and our AI offerings can help deliver life-saving benefits in the healthcare industry.